|October 14th, 2009|
Current Press Releases
Dr. Floyd Bloom Joins aTyr Pharma's Scientific Advisory Board
World Renown Neuroscientist Adds Pharmacology Insight on aTyr Pharma's Proprietary Protein Drug Candidates
San Diego, CA, October 14th, 2009 - aTyr Pharma announced today that Dr. Floyd Bloom Professor Emeritus, Molecular and Integrative Neuroscience Department at The Scripps Research Institute, has joined their scientific advisory board. A widely acknowledged leader in the field of neurosciences, Dr. Bloom has been recognized with many honors, including elected membership to the National Academy of Sciences, the Institute of Medicine, the American Philosophical Society and the Royal Swedish Academy of Science. With over 400 scientific publications to his name, Dr. Bloom brings rigorous and extensive scientific experience in understanding the biology and impact of drugs on human diseases. This scientific expertise and perspective will be extremely valuable to aTyr Pharma's novel class of biotherapeutics being discovered and developed to treat a wide variety of diseases, including neurological disorders. Based on an entirely new class of naturally occurring proteins, the aTyr Pharma drug pipeline consists of proteins hidden in the aminoacyl tRNA synthetases. Key enzymes in protein synthesis, aminoacyl tRNA synthetases have recently been shown to have resected forms arising from splice variations or proteolysis, known as resectins. These resectins have distinct functions not related to protein synthesis that can be exploited for development as biotherapeutics.
According to Jeff Watkins, Ph. D. and CEO of aTyr Pharma , "Developing a new class of biologics with applications in a number of therapeutic areas such as inflammation, cardiovascular, hematology, neurology and metabolism requires deep knowledge in particular disease areas. Dr. Bloom is the consummate scientist in the field of neurobiology, and has shown ability to translate that knowledge into human therapies by his founding and role as CEO at Neurome. We are thrilled to be able to apply his knowledge and expertise to our understanding of resectin biology."
Professor Paul Schimmel, co-founder of aTyr Pharma , fellow National Academy member and Professor at the Scripps Research Institute added, "I have known, respected and admired Dr. Bloom's integrity and scientific excellence for decades. Dr. Bloom's unparalleled expertise brings additional scientific authority to what was already a world class scientific advisory board at aTyr Pharma . Dr. Bloom's influence and guidance, will help us accelerate our understanding and development of aTyr Pharma's novel class of therapeutic proteins."
About Dr. Bloom
About aTyr Pharma